Evidence map›Paper›PMID 42837064›Full record

ArticleMolecular neurobiology2026

A Live-Cell Imaging System for the Identification of Pro- and Anti-Aggregatory α-Synuclein Modulators.

Tzukit Tal, Yael Almog, Ortal Iancu Cohen, Lihi Radomir, Dana Bar-On, Ianai Fishbein, Eran Meshorer

Abstract read
In one paragraph

Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tzukit TalDepartment of Genetics, The Institute of Life Sciences, The Edmond J. Safra Campus, The Hebrew University, 9190401, Jerusalem, Israel.
Yael AlmogNon-Clinical Development Department, Teva Pharmaceutical Industries Ltd, 4250483, Netanya, Israel.
Ortal Iancu CohenNon-Clinical Development Department, Teva Pharmaceutical Industries Ltd, 4250483, Netanya, Israel.
Lihi RadomirNon-Clinical Development Department, Teva Pharmaceutical Industries Ltd, 4250483, Netanya, Israel.
Dana Bar-OnNon-Clinical Development Department, Teva Pharmaceutical Industries Ltd, 4250483, Netanya, Israel.
Ianai FishbeinNon-Clinical Development Department, Teva Pharmaceutical Industries Ltd, 4250483, Netanya, Israel. Ianai.Fishbein@teva.co.il.
Eran MeshorerDepartment of Genetics, The Institute of Life Sciences, The Edmond J. Safra Campus, The Hebrew University, 9190401, Jerusalem, Israel. eran.meshorer@mail.huji.ac.il.ORCID https://orcid.org/0000-0003-4777-986X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

α-Synuclein (αSyn) aggregation is a defining pathological feature of synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy (MSA). However, existing in vitro methods to monitor αSyn aggregation often rely on endpoint assays that cannot distinguish monomeric from oligomeric species or capture early aggregation dynamics. Here, we implement an αSyn bimolecular fluorescence complementation (αSyn-BiFC) strategy in a stable human glial-derived cell system optimized for real-time, high-content analysis of early αSyn self-association events and their modulation. In this strategy, αSyn is fused to complementary fragments of the Venus fluorescent protein, enabling real-time visualization of αSyn-αSyn interactions during oligomer formation. Using U373 human astrocytoma cells, a scalable glial-derived cell line previously used in studies of MSA, we established both transient and stable αSyn-BiFC expression systems. We demonstrate that reconstituted Venus fluorescence correlates with pSer129 αSyn immunostaining, supporting the association of the BiFC signal with pathology-related αSyn assemblies. The model responded robustly to multiple stressors known to promote αSyn aggregation, including proteostasis disruption (leupeptin, MG132), ER stress (tunicamycin), and environmental toxins (rotenone), while iron, particularly Fe

Indexed as

alpha-SynucleinProtein AggregatesProtein Aggregation, PathologicalCell Line, TumorHumansNeurogliaalpha-SynucleinProtein AggregatesAggregationAlpha-synucleinBiFCBimolecular fluorescence complementationDrug screeningHigh-content imagingLive-cell imagingSynucleinopathiesU373 cells

Identifiers

PMID42837064
PMCPMC13642413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.